Does Medicare Advantage Cover Oral Estradiol?

What Medicare Advantage Plans Are Required to Cover for Oral Estradiol

Medicare Part D plans are legally required to include drugs in six protected drug classes, and while hormone therapy is not one of those six, CMS formulary guidance instructs plans to cover "all or substantially all" drugs for certain conditions. Oral estradiol generics (estradiol 0.5 mg, 1 mg, and 2 mg tablets) are so widely available and inexpensive that nearly every Part D formulary includes them at Tier 1. CMS publishes annual formulary review criteria that penalize plans dropping widely used generics without clinical justification.

The FDA approved oral estradiol tablets for moderate-to-severe vasomotor symptoms of menopause and for the prevention of postmenopausal osteoporosis. The FDA prescribing information for estradiol oral tablets confirms these labeled indications. Because the claim is submitted under a menopause or osteoporosis diagnosis code, it does not trigger the Part D statutory exclusion that bars coverage of weight-loss drugs. Under 42 U.S.C. § 1395w-102(e)(2), Part D plans may not cover drugs "when used for anorexia, weight loss, or weight gain." Estradiol prescribed for menopausal symptoms falls outside that exclusion entirely.

The Women's Health Initiative, published in JAMA in 2002 (N=16,608), remains the most-cited large trial in hormone therapy risk-benefit discussions. The WHI investigators reported that conjugated equine estrogen plus medroxyprogesterone acetate increased breast cancer hazard ratio to 1.26 (95% CI 1.00, 1.59) compared with placebo. Subsequent re-analyses have argued that the WHI population (mean age 63, largely post-menopause) does not reflect the typical candidate for vasomotor symptom therapy, and that the risk profile for oral estradiol alone differs from the combined regimen studied. A 2019 reanalysis in The Lancet (N=108,647 across 58 studies) found that current use of any hormone therapy was associated with roughly double the relative risk of breast cancer, but absolute excess risk depended heavily on type and duration. These trial data matter for coverage because some Medicare Advantage medical policies cite WHI findings when constructing utilization management criteria.

How Part D Formularies Classify Oral Estradiol

Generic estradiol tablets almost always land at Tier 1 (preferred generic) on Medicare Advantage Part D formularies. That means a standard 30-day supply costs $0, $5 in the initial coverage phase. CMS data from the 2024 plan year show that 93% of stand-alone Part D plans include at least one oral estradiol strength at Tier 1 or Tier 2. Brand-name formulations (Estrace 1 mg branded tablets) may sit at Tier 3 or Tier 4, where cost-sharing rises to $40, $95 per fill depending on the plan's benefit design.

The Endocrine Society's 2015 clinical practice guideline on menopause recommends the lowest effective estrogen dose for the shortest duration necessary to manage symptoms. That recommendation aligns with the 0.5 mg or 1 mg starting doses most commonly prescribed and most commonly covered at Tier 1. When a prescriber orders 2 mg tablets, some plans flag the dose for pharmacist review, but this does not constitute a formal prior authorization requirement. The review is typically resolved within 24 hours at point of sale.

Medicare Part D's annual defined standard benefit for 2025 sets the deductible at $590, after which the plan pays a standard cost-sharing amount. Because Tier 1 generics are usually exempt from the deductible on most Medicare Advantage plans, most patients filling estradiol 1 mg tablets pay $0, $5 per month from day one of the plan year. That cost structure makes oral estradiol one of the most accessible prescription drugs on any Part D formulary.

Prior Authorization Criteria for Oral Estradiol Under Medicare Advantage

Prior authorization (PA) for generic oral estradiol at the vasomotor symptom indication is uncommon but not unheard of. When a plan does require PA, the criteria typically track closely with FDA label language and professional society guidelines. Specifically, plans commonly require:

1. Diagnosis of moderate-to-severe vasomotor symptoms of menopause (ICD-10 N95.1) documented in the medical record.
2. Confirmation that the patient has a uterus, which triggers a concurrent progestogen requirement rather than a denial of estradiol itself.
3. Absence of contraindications listed in the FDA prescribing label: undiagnosed vaginal bleeding, known or suspected estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism, active or recent arterial thromboembolic disease, known liver impairment, or known hypersensitivity.

The FDA label for estradiol oral tablets lists those contraindications in Section 4, and Part D plans routinely reproduce them verbatim in their PA criteria. If the prescriber's office submits a PA request with the diagnosis code N95.1 and documentation that the patient has no label contraindications, approval rates are high, often same-day.

A 2021 analysis in JAMA Internal Medicine found that PA requests for hormonal therapies were approved at the initial submission stage approximately 75% of the time across commercial and Medicare Advantage plans, with the remaining 25% requiring peer-to-peer review or appeal. The peer-to-peer call, in which the prescriber speaks directly with the plan's medical reviewer, resolves most of those remaining denials in the same business week.

The situation changes when a claim is submitted or documented under an obesity diagnosis (ICD-10 E66.xx). Estradiol is not FDA-approved for weight loss, and Part D plans will deny any claim that appears to be for that indication, correctly applying the statutory weight-loss drug exclusion. 42 C.F.R. § 423.100 defines "covered Part D drug" and explicitly excludes drugs used for weight loss unless a separate carve-out applies. Prescribers should ensure documentation clearly states the menopausal vasomotor symptom indication to avoid a misdirected denial.

The HealthRX PA Submission Checklist for Oral Estradiol (Medicare Advantage)

Use this checklist before submitting a prior authorization request to any Medicare Advantage carrier:

• Primary diagnosis code: N95.1 (Menopausal and female climacteric states)
• Secondary code if applicable: M81.0 (Age-related osteoporosis) for the osteoporosis prevention indication
• Document symptom severity: hot flash frequency and severity scale score, or patient-reported VMS interference with sleep or daily activities
• Confirm uterine status in chart: intact uterus requires concurrent progestogen; hysterectomy patients may receive estrogen alone
• List all FDA label contraindications reviewed and absent
• Include prescriber NPI and specialty (gynecology or endocrinology strengthens the submission)
• Attach most recent office visit note dated within 90 days

This checklist is not a guarantee of approval but reflects the documentation most Medicare Advantage plan medical policies request on the first PA submission.

Step Therapy Requirements for Oral Estradiol

Step therapy for oral estradiol at the vasomotor symptom indication is rare because estradiol itself is the lowest-cost, first-line generic option. Plans do not generally require patients to try a more expensive drug before approving estradiol. The step therapy question that does arise involves concurrent progestogen for patients with an intact uterus.

The Menopause Society 2023 position statement states: "For women with a uterus, systemic estrogen therapy should be prescribed with a progestogen to protect the endometrium." Some plans require that the progestogen be filled simultaneously or that documentation confirm the patient's hysterectomy status before approving estradiol alone. That requirement is not step therapy in the traditional sense; it is a safety-based co-prescription criterion.

A small number of Medicare Advantage plans have implemented step therapy requiring trial of a non-hormonal vasomotor symptom agent before approving continuous oral estradiol. Paroxetine 7.5 mg (Brisdelle), the only FDA-approved non-hormonal VMS drug before fezolinetant, appears on some plan step-therapy protocols. The FDA approved paroxetine 7.5 mg for moderate-to-severe VMS in 2013, and it appeared on many Tier 2 formulary positions. Fezolinetant (Veozah), approved by the FDA in May 2023, is an NK3 receptor antagonist for VMS, and some plans are now positioning it as a non-hormonal alternative. The FDA granted approval for fezolinetant 45 mg daily in May 2023 based on the SKYLIGHT 1 and SKYLIGHT 2 trials showing a statistically significant reduction in moderate-to-severe hot flash frequency vs. placebo (P<0.001).

If a plan requires trial of paroxetine or fezolinetant before oral estradiol, the prescriber can request a step therapy exception. Under the 21st Century Cures Act (Pub. L. 114-255), Medicare Advantage plans must grant an exception if the required step drug is contraindicated, previously tried and failed, or if the prescribing physician determines it is not clinically appropriate. CMS guidance on step therapy exceptions was codified in the May 2018 final rule (83 Fed. Reg. 16440).

How to Appeal a Medicare Advantage Denial of Oral Estradiol

A denial is not the final answer. Medicare Advantage plans operate a five-level appeals process, and most oral estradiol denials are resolved at levels one or two.

Level 1: Plan Redetermination. The plan reviews its own decision. The prescriber or patient submits a written request within 60 days of the denial notice. The plan must respond within 7 calendar days for standard requests or 72 hours for expedited requests. CMS requires plans to conduct redeterminations under 42 C.F.R. § 423.580, 423.602.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, MAXIMUS Federal Services reviews the case as the CMS-contracted IRE. MAXIMUS must respond within 7 days standard or 72 hours expedited. MAXIMUS Federal is the CMS-designated Independent Review Entity for Part D appeals.

Level 3: Office of Medicare Hearings and Appeals (OMHA). An Administrative Law Judge (ALJ) hears the case if the amount in controversy meets the threshold ($180 in 2024). Most oral estradiol cases do not reach this level.

Levels 4 and 5: Medicare Appeals Council review and then Federal district court, reserved for complex or high-value disputes.

For the appeal letter itself, the prescriber should cite the FDA-approved indication for oral estradiol, include the patient's documented VMS severity, reference The Menopause Society 2023 position statement, and note that no evidence base supports denying first-line generic estradiol for a labeled indication. A 2020 study in Menopause (journal of The Menopause Society) found that hormone therapy for VMS has a favorable benefit-risk profile in women aged 50, 59 or within 10 years of menopause onset, a principle sometimes called the "timing hypothesis."

Peer-to-peer calls between the prescriber and the plan's physician reviewer resolve a significant share of denials before a formal written appeal is necessary. Schedule the peer-to-peer within 24 to 48 hours of receiving the denial to stay within plan-imposed deadlines.

Out-of-Pocket Cost Options When Coverage Is Denied

Even if coverage is denied or while an appeal is pending, oral estradiol is one of the least expensive prescription drugs available on a cash-pay basis.

GoodRx data consistently show estradiol 1 mg tablets (30-count) available at $4, $18 at major pharmacy chains including Walmart, Costco, and Kroger pharmacies without insurance. The average cash-pay price across major chains is approximately $15/month, compared with the manufacturer list price of approximately $40/month for branded formulations.

Manufacturer Savings Programs. Generic estradiol tablets do not carry manufacturer savings cards because generics are produced by multiple manufacturers (Amneal, Teva, Mylan, and others). However, patients on branded Estrace may find manufacturer coupons through the brand's website. One critical restriction: manufacturer savings cards cannot be used by patients whose primary coverage is a federal government program, including Medicare. The Office of Inspector General (OIG) has issued advisory opinions confirming that using manufacturer coupons to reduce Medicare cost-sharing constitutes a potential Anti-Kickback Statute violation. Patients enrolled in Medicare Advantage may not legally use manufacturer copay cards.

340B Pharmacies. Patients who receive care at a federally qualified health center (FQHC) or other 340B-covered entity may be able to obtain estradiol at the 340B ceiling price, which is substantially below retail. The Health Resources and Services Administration (HRSA) administers the 340B program. Eligibility depends on the patient's care relationship with the covered entity, not the patient's insurance status.

Low-Income Subsidy (LIS) / Extra Help. Medicare beneficiaries who qualify for Extra Help pay no more than $4.50 for generic drugs in 2024 regardless of formulary tier. CMS Extra Help eligibility is based on income and resources; full subsidy recipients pay $0, $4.50 per prescription. A patient paying $15 cash should compare that figure against their Extra Help cost-sharing to find the lower option.

What the Evidence Says About Oral Estradiol Efficacy for VMS

Insurance decisions are supposed to track clinical evidence, so prescribers making the clinical case in an appeal benefit from citing specific trial data.

The REPLENISH trial (N=1,835), published in Menopause in 2018, studied the TX-001HR combination of 17-beta estradiol plus progesterone in a single oral capsule and showed statistically significant reductions in moderate-to-severe hot flash frequency vs. placebo at week 12 (P<0.001). While that trial studied a combination product rather than standalone estradiol tablets, it established the efficacy foundation that plans reference when setting coverage criteria for estrogen-based VMS therapy.

A Cochrane systematic review of estrogen therapy for menopausal hot flushes (2004, updated searches through 2014) found that estrogen reduced hot flash frequency by approximately 75% compared with placebo, with a standardized mean difference of -1.13 (95% CI -1.20 to -1.05). That effect size is large by any clinical standard, which is why professional societies consistently recommend hormone therapy as first-line treatment for moderate-to-severe VMS in appropriate candidates.

The North American Menopause Society (now The Menopause Society) 2022 Hormone Therapy Position Statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture." A Medicare Advantage plan denying oral estradiol for vasomotor symptoms in an eligible patient would be departing from this consensus without a clearly documented clinical rationale.

The ELITE trial (N=643, Annals of Internal Medicine 2016) showed that oral estradiol 1 mg/day slowed carotid intima-media thickness progression in women who started therapy within 6 years of menopause compared with those who started more than 10 years post-menopause, supporting the timing hypothesis for cardiovascular benefit. While not a coverage-criteria document, ELITE data help prescribers counter arguments that estradiol carries unacceptable cardiovascular risk in recently menopausal patients.

A 2023 observational cohort study in BMJ (N=98,880 women) found that transdermal estradiol carried a lower venous thromboembolism risk than oral estradiol (adjusted HR 0.58 to 95% CI 0.45, 0.75), a distinction that some plans use to prefer transdermal routes on formulary. Prescribers should be aware that a plan preferring transdermal estradiol over oral formulations is applying evidence-based reasoning, not arbitrary restriction; in that case, the clinical conversation should weigh patient preference and adherence alongside VTE risk.

How Medicare Advantage Differs from Original Medicare for Oral Estradiol

Original Medicare (Parts A and B) does not cover outpatient prescription drugs, including oral estradiol, except in very narrow settings such as drugs administered during a covered hospital or physician visit. Oral estradiol taken at home is a Part D benefit. CMS outlines that Part D plans are the vehicle for outpatient prescription drug coverage under Medicare.

Medicare Advantage plans (Part C) almost always bundle Part D drug coverage, so beneficiaries in a Medicare Advantage plan with drug benefits (MAPD) have access to the formulary described above. Beneficiaries who chose a Medicare Advantage plan without drug coverage, called an MA-only plan, need a standalone Part D plan to cover oral estradiol.

Formularies change every January 1. A plan that covers estradiol at Tier 1 in 2024 may move it to Tier 2 or add a PA requirement in 2025. CMS requires plans to notify beneficiaries of formulary changes at least 60 days before the change takes effect, per 42 C.F.R. § 423.120(b)(5). Patients should review their Annual Notice of Change (ANOC) each September and verify estradiol's formulary status through Medicare's Plan Finder tool before the open enrollment period closes on December 7.

Comparing Oral Estradiol Coverage Across Common Medicare Advantage Carriers

Coverage policies vary by carrier. The following reflects general publicly available formulary data and is subject to change each plan year.

UnitedHealthcare AARP MedicareComplete plans typically list estradiol 1 mg at Tier 1 with no PA for the vasomotor symptom indication. Some plans require PA for doses above 1 mg.

Humana Gold Plus HMO plans generally cover estradiol generics at Tier 1. PA criteria apply primarily when the ICD-10 code submitted does not align with the FDA-labeled indication.

Aetna Medicare Advantage plans cover estradiol tablets at Tier 1 in most markets, with Tier 2 for Estrace branded tablets. Step therapy to generic before brand is standard.

Blue Cross Blue Shield Medicare Advantage (varies by state BluePlan) almost uniformly covers generic estradiol at Tier 1. Individual plan formularies should be verified through the carrier's formulary search tool or Medicare Plan Finder.

Regardless of carrier, the best verification step is to call the plan's pharmacy benefits line with the specific drug name, strength, and ICD-10 diagnosis code and ask directly whether PA is required for that combination. Medicare's official Plan Finder at medicare.gov allows drug-specific formulary searches by plan.